BACKGROUND AND PURPOSE: Results from several studies point to voltage-gated Na(+) channels as potential mediators of the immobility produced by inhaled anaesthetics. We hypothesized that the intrathecal administration of tetrodotoxin, a drug that blocks Na(+) channels, should enhance anaesthetic potency, and that concurrent administration of veratridine, a drug that augments Na(+) channel opening, should reverse the increase in potency. EXPERIMENTAL APPROACH: We measured the change in isoflurane potency for reducing movement in response to a painful stimulus as defined by MAC (minimum alveolar concentration of anaesthetic required to abolish movement in 50% of subjects) caused by intrathecal infusion of various concentrations of tetrodotoxin into the lumbothoracic subarachnoid space of rats, and the change in MAC caused by the administration of a fixed dose of tetrodotoxin plus various doses of intrathecal veratridine. KEY RESULTS: Intrathecal infusion of tetrodotoxin (0.078-0.63 microM) produced a reversible dose-related decrease in MAC, of more than 50% at the highest concentration. Intrathecal co-administration of veratridine (1.6-6.4 microM) reversed this decrease in a dose-related manner, with nearly complete reversal at the highest veratridine dose tested. CONCLUSIONS AND IMPLICATIONS: Intrathecal administration of tetrodotoxin increases isoflurane potency (decreases isoflurane MAC), and intrathecal administration of veratridine counteracts this effect in vivo. These findings are consistent with a role for voltage-gated Na(+) channel blockade in the immobility produced by inhaled anaesthetics.
BACKGROUND AND PURPOSE: Results from several studies point to voltage-gated Na(+) channels as potential mediators of the immobility produced by inhaled anaesthetics. We hypothesized that the intrathecal administration of tetrodotoxin, a drug that blocks Na(+) channels, should enhance anaesthetic potency, and that concurrent administration of veratridine, a drug that augments Na(+) channel opening, should reverse the increase in potency. EXPERIMENTAL APPROACH: We measured the change in isoflurane potency for reducing movement in response to a painful stimulus as defined by MAC (minimum alveolar concentration of anaesthetic required to abolish movement in 50% of subjects) caused by intrathecal infusion of various concentrations of tetrodotoxin into the lumbothoracic subarachnoid space of rats, and the change in MAC caused by the administration of a fixed dose of tetrodotoxin plus various doses of intrathecal veratridine. KEY RESULTS: Intrathecal infusion of tetrodotoxin (0.078-0.63 microM) produced a reversible dose-related decrease in MAC, of more than 50% at the highest concentration. Intrathecal co-administration of veratridine (1.6-6.4 microM) reversed this decrease in a dose-related manner, with nearly complete reversal at the highest veratridine dose tested. CONCLUSIONS AND IMPLICATIONS: Intrathecal administration of tetrodotoxin increases isoflurane potency (decreases isoflurane MAC), and intrathecal administration of veratridine counteracts this effect in vivo. These findings are consistent with a role for voltage-gated Na(+) channel blockade in the immobility produced by inhaled anaesthetics.
Authors: Yi Zhang; Manohar Sharma; Edmond I Eger; Michael J Laster; Hugh C Hemmings; R Adron Harris Journal: Anesth Analg Date: 2008-09 Impact factor: 5.108
Authors: Yi Zhang; Michael J Laster; Koji Hara; R Adron Harris; Edmond I Eger; Caroline R Stabernack; James M Sonner Journal: Anesth Analg Date: 2003-01 Impact factor: 5.108
Authors: Annika F Barber; Vincenzo Carnevale; Michael L Klein; Roderic G Eckenhoff; Manuel Covarrubias Journal: Proc Natl Acad Sci U S A Date: 2014-04-21 Impact factor: 11.205
Authors: Joel P Baumgart; Zhen-Yu Zhou; Masato Hara; Daniel C Cook; Michael B Hoppa; Timothy A Ryan; Hugh C Hemmings Journal: Proc Natl Acad Sci U S A Date: 2015-09-08 Impact factor: 11.205
Authors: Dan M McEntire; Daniel R Kirkpatrick; Nicholas P Dueck; Mitchell J Kerfeld; Tyler A Smith; Taylor J Nelson; Mark D Reisbig; Devendra K Agrawal Journal: Expert Rev Clin Pharmacol Date: 2016-05-23 Impact factor: 5.045
Authors: Francisco Rafael Nieto; Enrique José Cobos; Miguel Ángel Tejada; Cristina Sánchez-Fernández; Rafael González-Cano; Cruz Miguel Cendán Journal: Mar Drugs Date: 2012-01-31 Impact factor: 6.085
Authors: Karl F Herold; R Lea Sanford; William Lee; Margaret F Schultz; Helgi I Ingólfsson; Olaf S Andersen; Hugh C Hemmings Journal: J Gen Physiol Date: 2014-11-10 Impact factor: 4.086